XENPOZYME DIN 02545713
Status: Approved
Holder: SANOFI-AVENTIS CANADA INC
Health Canada record
| Active ingredient(s) | OLIPUDASE ALFA 4 MG |
|---|
| Dosage form | Powder For Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | A16AB25 OLIPUDASE ALFA |
|---|
| Original market date | |
|---|
| Current status date | 28-Feb-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing OLIPUDASE ALFA
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02545721 | XENPOZYME | SANOFI-AVENTIS CANADA INC | Powder For Solution | OLIPUDASE ALFA 20 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 32782 | 2024-02-28 | New Drug Submission (NDS) | |
Request a quote for XENPOZYME
How to read a Canadian DIN record